|
[ SPOREs:
|
|
|
|
|
|
|
|
|
|
|
|
|
]
Genitourinary (GU) SPOREs
Presently, there are two GU SPOREs. Bladder Cancer was initiated in 2001,
and the SPORE in Renal Cancer began in 2003. Bladder cancer is a highly
prevalent disease, with an estimated 61,000 new cases and 13,000 deaths
in 2006. It is estimated that there will be nearly 39,000 new cases
of cancers of kidney and renal pelvis in 2006 and nearly 13,000 deaths.
In developing their cancer interventions through molecular-based translational
research, the GU SPOREs have established national and international consortia
to conduct studies aimed at improving the development and implementation
of biomarkers and new therapeutic regimens.
To view the associated abstract, click on the name/address below.
|
Colin P. Dinney, M.D.
University of Texas
MD Anderson Cancer Center
1515 Holcombe Boulevard, Box 446
Houston, TX 77030
Tel: (713) 792-3250
Fax: (713) 794-4824
For more information on this specific SPORE's institution, please visit: http://www.mdanderson.org/departments/bladderSPORE/
|
Michael Atkins, M.D.
Director, Cutaneous Oncology and Biologic Therapy Programs
Deputy Director, Hematology / Oncology
Beth Israel Deaconess Medical Center
330 Brookline Avenue, Kirstein 153
Boston, MA 02115
Tel: (617) 667-1930
Fax: (617) 975-8030
For more information on this specific SPORE's institution, please visit: http://www.dfhcc.harvard.edu/renalcancer
|
|
